AZP-531

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Azp-531 is a disacylated ghrelin used to improve blood sugar control and weight loss.

Azp-531 is a disacylated ghrelin used to improve blood sugar control and weight loss.(In Vitro):AZP-531 exerts survival effects on pancreatic b-cells and human pancreatic islets which is comparable to that of UAG, the parent molecule. AZP-531 is very stable in human plasma in vitro. No degradation is observed after 1 day of incubation at 37°C.(In Vivo):The highest concentration of this peptide is 4350 ng/mL, and the majority of samples are above the limit of quantification (1 ng/mL). AZP-531 infusion prevents the increase in body weight caused by high-fat diet in mice. AZP-531 treatment prevents high-fat diet-induced proinflammatory effects, stimulates expression of mitochondrial function markers in brown adipose tissue, and prevents development of a prediabetic metabolic state. AZP-531 also prevents a high-fat diet-induced increase in acyl ghrelin levels. AZP-531 is well tolerated. Single- and multiple-dose pharmokinetic variables are similar. Maximum AZP-531 concentrations are typically reached at 1 h post-dose. Observed maximum concentration and area under the curve are dose-proportional. The mean terminal half-life is 2–3 h. AZP-531 (≥15 μg/kg) significantly improves glucose concentrations, without increasing insulin levels, suggesting an insulin-sensitizing effect. AZP-531 decreases mean body weight by 2.6 kg (vs 0.8 kg for placebo). Glucose variables improve in all groups, including placebo, suggesting a study effect in uncontrolled patients at baseline. AZP-531 60 μg/kg reduces HbA1c by 0.4% (vs 0.2% for placebo) and body weight by 2.1 kg (vs 1.3 kg for placebo).

——

Others

Other Targets

——

——

——

1088543-62-7

962

C40H63N15O13

>98% (HPLC)

DMSO : 100 mg/mL (103.95 mM; Need ultrasonic)

——

Sequence:Cyclo(Arg-Val-Gln-Ser-Pro-Glu-His-Gln)

(-20℃)

With Ice Pack

≥ 2 years